MAS-1 Adjuvanted Immunotherapy for Type 1 Diabetes (MER3101 Trial)

"According to the study's inclusions criteria, only those aged between 18 and 45 can participate. However, there are 228 trials for minors and 970 clinical studies catered toward seniors."

"Currently, 71 investigations into this particular intervention are taking place. 13 of these experiments have reached the third and final phase of research. While Cincinnati is home to most trials exploring this treatment, 247 different medical centers across the United States are involved in its development."

"This therapy has only been tested on a limited basis, so it was awarded an initial safety rating of 1."

"According to the public record on clinicaltrials.gov, this clinical trial is in an active recruitment phase and was initially listed at the end of August 2020 with its most recent update being published in May 2022."

"This medical trial is currently seeking 28 participants aged 18 to 45 with newly diagnosed diabetes mellitus. Additionally, the following criteria must be met: females of reproductive age require a negative pregnancy test and are obligated to abstain from conception until two months after study drug administration, ADA-approved T1DM diagnosis within the past 2 years, C-peptide levels ≥ 0.2 pmol/ml during an MMTT conducted 21 days post-diagnosis and before randomization, one month minimum since last immunization prior to enrolment in the clinical trial, intensive diabetes management compliant behaviour expected throughout duration of treatment; routine vaccinations prohibited for"

"Affirmative. Information hosted on clinicaltrials.gov indicates that this experiment, initially posted in August of 2020, is searching for 28 volunteers from 1 site to participate. The most recent update was May 4th 2022."